Skip to main content
. 2010 Aug 16;120(9):3209–3219. doi: 10.1172/JCI40034

Figure 6. RUNX3 binds PR3 and MPO genes in myeloid cell lines and in ANCA patients in remission.

Figure 6

(A) Consensus RUNX3 binding sites in PR3 intron 4 and MPO intron 7 and 3′ UTR. (B) ChIP analysis for RUNX3 binding to PR3 intron 4 and MPO intron 7 in undifferentiated or PMA-differentiated U937 cells under the indicated immunoprecipitation conditions. Normal rabbit serum was used in mock immunoprecipitation. Lanes were run on the same gel but were noncontiguous (white lines). (C–E) ChIP analysis for RUNX3 binding to MPO intron 7 and 3′ UTR (C and D) or to MPO intron 7 and PR3 intron 4 (E) in neutrophils from an active ANCA vasculitis patient (C) and from ANCA vasculitis patients in remission (D and E). Relative mRNA levels were determined by Taqman quantitative RT-PCR for MPO and PR3 from total leukocytes of ANCA vasculitis patients and calculated as fold change relative to healthy control, with exact values shown above bars. Lanes in E were run on the same gel but were noncontiguous (white line).